Agenus, a US-based biotechnology company headquartered in Lexington, specializes in immuno-oncology therapies targeting cancer and infectious diseases, employing 389 staff. Its pipeline includes advanced antibodies and various immunotherapy classes.
Agenus (AGEN) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Agenus's actual EPS was -$3.08, missing the estimate of -$2.38 per share, resulting in a -29.49% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
